1. Home
  2. CHCO vs XERS Comparison

CHCO vs XERS Comparison

Compare CHCO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

N/A

Current Price

$139.59

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$17.17

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHCO
XERS
Founded
1957
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CHCO
XERS
Price
$139.59
$17.17
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
★ $143.40
$17.29
AVG Volume (30 Days)
93.9K
★ 3.0M
Earning Date
10-26-2026
11-05-2026
Dividend Yield
★ 2.87%
N/A
EPS Growth
13.18
★ 100.00
EPS
★ 6.98
N/A
Revenue
N/A
★ $49,590,000.00
Revenue This Year
$4.82
$37.58
Revenue Next Year
$3.77
$31.16
P/E Ratio
$19.94
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$113.21
$5.25
52 Week High
$148.99
$16.98

Technical Indicators

Market Signals
Indicator
CHCO
XERS
Relative Strength Index (RSI) 38.82 86.63
Support Level $120.71 $5.90
Resistance Level $146.69 N/A
Average True Range (ATR) 2.63 0.71
MACD -0.48 0.38
Stochastic Oscillator 0.00 97.43

Price Performance

Historical Comparison
CHCO
XERS

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: